Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Serafini

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Immunologic Research|November 9, 2013
Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the uglyPaolo Serafini
Vaccines|September 13, 2016
Neutrophils and Granulocytic MDSC: The Janus God of Cancer ImmunotherapySerena Zilio, Paolo Serafini
Seminars in Cancer Biology|September 20, 2005
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppressionPaolo Serafini, Ivan Borrello, Vincenzo Bronte
Computers & Operations Research|November 5, 2013
Exact solution of the robust knapsack problemMichele Monaci, Ulrich Pferschy, Paolo Serafini
Cancer Research|July 3, 2008
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cellsPaolo Serafini, Stephanie Mgebroff, Kimberly Noonan, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumorSerena Zilio, Silvio Bicciato, Donald Weed, et al.
Immunologic Research|November 13, 2013
The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunitiesMonika E Freiser, Paolo Serafini, Donald T Weed
Immunological Reviews|March 28, 2008
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cellsIlaria Marigo, Luigi Dolcetti, Paolo Serafini, et al.
Trends in Immunology|June 18, 2003
L-arginine metabolism in myeloid cells controls T-lymphocyte functionsVincenzo Bronte, Paolo Serafini, Alessandra Mazzoni, et al.
Urology|June 30, 2019
Optimized Clinical Decision-making: A Configurable Markov Model for Benign Prostatic Hyperplasia TreatmentSimone Crivellaro, Laurel Sofer, Whitney R Halgrimson, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Immunologic Research|November 9, 2013
Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the uglyPaolo Serafini
Vaccines|September 13, 2016
Neutrophils and Granulocytic MDSC: The Janus God of Cancer ImmunotherapySerena Zilio, Paolo Serafini
Seminars in Cancer Biology|September 20, 2005
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppressionPaolo Serafini, Ivan Borrello, Vincenzo Bronte
Computers & Operations Research|November 5, 2013
Exact solution of the robust knapsack problemMichele Monaci, Ulrich Pferschy, Paolo Serafini
Cancer Research|July 3, 2008
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cellsPaolo Serafini, Stephanie Mgebroff, Kimberly Noonan, et al.
Journal for Immunotherapy of Cancer|January 22, 2022
CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumorSerena Zilio, Silvio Bicciato, Donald Weed, et al.
Immunologic Research|November 13, 2013
The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunitiesMonika E Freiser, Paolo Serafini, Donald T Weed
Immunological Reviews|March 28, 2008
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cellsIlaria Marigo, Luigi Dolcetti, Paolo Serafini, et al.
Trends in Immunology|June 18, 2003
L-arginine metabolism in myeloid cells controls T-lymphocyte functionsVincenzo Bronte, Paolo Serafini, Alessandra Mazzoni, et al.
Urology|June 30, 2019
Optimized Clinical Decision-making: A Configurable Markov Model for Benign Prostatic Hyperplasia TreatmentSimone Crivellaro, Laurel Sofer, Whitney R Halgrimson, et al.
Pageof 4